ProKidney Corp. Class A
(NASDAQ: PROK)

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

3.290

+0.030 (+0.92%)
Jarak 3.160 - 3.500   (10.76%)
Buka 3.385
Tutup Terdahulu 3.260
Harga Beli 10.640
Beli Purata 10
Jual Beli 10.730
Purata Jual 8
Purata 2,775,401
Nilai -
Catatan
Harga tertunda. Dikemas kini pada 26 Jul 2025 04:00.
Data dikuasakan oleh
Lihat Semua Acara

Kongsi idea pelaburan anda
Please login to view stock data and analysis